BW VACCINE SURGE MEETING 6 DEC 90

File: 970107_sep96_decls59_0002.txt
Page: 0002
Total Pages: 3

Subject: BW VACCINE SURGE MEETING  6 DEC 90                              

Unit: OTSG        

Parent Organization: HSC         

Box  ID: BX003201

Folder Title: BW VACCINE SURGE MEETING                                                                        

Document Number:       1001

Folder Seq  #:         23



                                    UNCLASSIFIED







         DASG-PSZ
         SUBJECT: BW VACCINE SURGE MEETING

              d.                                              This company
         is currently doing research on botulinumtoxin serotype F under
         contract from MRDC but will convert to production of serotype E
         and then C this week. This will allow combining with existing
         stocks of types A,B and D to make a pentavalent vaccine.

              e. Michigan Public Health Service @ew Contract).

              (1) This is the same organization that is currently
         producing the anthrax vaccine (see a). Michigan is taking the
         individual botulinum serotypes and combining them to a
         pentavalent vaccine and packaging multi-dose vials.   They are
         able to produce botulinum monovalent vaccine as well within
         existing space and facilities but renovation is needed. It is
         unclear how much this would cost or what is required. A proposal
         is due this week.

              (2) It is possible that once the National Cancer Institute
         is producing the large amounts of anthrax vaccine, by mid March,
         that the Michigan anthrax vaccine production can be stopped and
         the fermenters converted to producing serotypes for the
         pentavalent botulinum vaccine. There is no estimate on money
         requirements but this should be available within a week.

              f. USAMRIID (Botulinum Vaccine Production). Colonel Ronald
         Williams, Commander of USAMRIID briefed the working group on the
         pros and cons of converting to such production. His briefing is
         at Enclosure 2. Essentially he stated that with relatively minor
         modification production of two serotypes could begin within 30
         days. Personnel are already vaccinated to meet good
         manufacturing standards and good labor standards, however, it
.
         He was also concerned about the change in the mission from one of
         research to that of production and the lack of experience anyone
         there has had with production. He referred to a group of
         consultants experienced in vaccine production who had toured the
         facility and would make recommendations as to the feasibility of
         conversion. Therefore a meeting was set for later in the week to
         further discuss the issue and make the required recommendation to
         ASD(HA).




                                   UNCLASSIFIED

Document 3 f:/Week-36/BX003201/BW VACCINE SURGE MEETING/bw vaccine surge meeting 6 dec 90:01029715474660
Control Fields 17
File Room = sep96_declassified
File Cabinet = Week-36
Box ID = BX003201
Unit = OTSG
Parent Organization = HSC
Folder Title = BW VACCINE SURGE MEETING
Folder Seq # = 23
Subject = BW VACCINE SURGE MEETING 6 DEC 90
Document Seq # = 1001
Document Date =
Scan Date =
Queued for Declassification = 01-JAN-1980
Short Term Referral = 01-JAN-1980
Long Term Referral = 01-JAN-1980
Permanent Referral = 01-JAN-1980
Non-Health Related Document = 01-JAN-1980
Declassified = 02-JAN-1997